Loading...
XTAE
BONS
Market cap73mUSD
May 22, Last price  
22.50ILS
1D
-2.60%
1Q
23.63%
Jan 2017
-60.80%
Name

Bonus Biogroup Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
32.71%
Rev. gr., 5y
%
Revenues
0k
Net income
-29m
L-26.29%
-17,973,000-9,701,000-11,207,000-13,459,000-16,046,000-20,197,000-18,735,000-22,240,000-22,021,000-90,076,000-38,703,000-28,529,000
CFO
-21m
L-19.03%
-9,672,000-7,631,000-7,907,000-8,069,000-9,625,000-11,823,000-13,427,000-13,113,000-15,746,000-39,839,000-28,815,000-26,397,000-21,374,000

Profile

Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products include BonoFill for bone tissue regeneration in maxillofacial and orthopedic indications; and MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS, as well as other life-threatening acute inflammatory diseases. Its products in pipeline comprise bone augmentation in osteoporosis patients; novel nano-materials for drug delivery; vascularized bone grafts; and soft tissue grafts. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel.
URL
http://www.bonusbiogroup.com
IPO date
Aug 20, 1993
Employees
57
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
29,790
8,850
Unusual Expense (Income)
NOPBT
(29,790)
(8,850)
NOPBT Margin
Operating Taxes
7,258
Tax Rate
NOPAT
(29,790)
(16,108)
Net income
(28,529)
-26.29%
(38,703)
-57.03%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,850
3,339
BB yield
-2.80%
Debt
Debt current
1,659
1,484
1,354
Long-term debt
18,725
20,832
22,550
Deferred revenue
Other long-term liabilities
Net debt
13,525
9,379
(29,720)
Cash flow
Cash from operating activities
(21,374)
(26,397)
(28,815)
CAPEX
(342)
(824)
(6,389)
Cash from investing activities
12,653
(14,257)
(6,293)
Cash from financing activities
2,552
(1,155)
2,135
FCF
11,297
(37,152)
(20,916)
Balance
Cash
6,859
12,937
53,624
Long term investments
Excess cash
6,859
12,937
53,624
Stockholders' equity
(34,289)
(7,078)
19,576
Invested Capital
51,438
47,541
48,765
ROIC
ROCE
EV
Common stock shares outstanding
1,167,925
621,084
Price
0.11
-35.33%
0.17
-13.02%
0.19
-84.76%
Market cap
195,043
63.56%
119,248
-83.66%
EV
204,422
89,528
EBITDA
2,793
(27,029)
(6,187)
EV/EBITDA
Interest
891
Interest/NOPBT